To explore this further, we used the pan-caspase inhibitor z-VAD-FMK, which effectively inhibited caspase-3/–7 activity in CTX-treated cells without preventing cancer cell arrest and eventual death, as determined by PI staining (Fig. 2a, Supplementary Fig. 2a, b). The gene discussed is CASP3; the disease is cancer.